Deep knowledge on 
 small-molecule drugs and 
 the 110,000 global patents 
 covering them 

Free Patent Expiration Alerts


Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

CANCIDAS Drug Profile

« Back to Dashboard
Cancidas is a drug marketed by Merck and is included in one NDA. It is available from one supplier. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-three patent family members in forty-seven countries.

The generic ingredient in CANCIDAS is caspofungin acetate. There are seven drug master file entries for this compound. One supplier is listed for this compound. There are two tentative approvals for this compound. Additional details are available on the caspofungin acetate profile page.

Summary for Tradename: CANCIDAS

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list1

Pharmacology for Tradename: CANCIDAS

Ingredient-typeLipopeptides
Drug ClassEchinocandin Antifungal

Clinical Trials for: CANCIDAS

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck
CANCIDAS
caspofungin acetate
INJECTABLE;IV (INFUSION)021227-001Jan 26, 2001RXYes6,136,783*PED<disabled>Y<disabled>
Merck
CANCIDAS
caspofungin acetate
INJECTABLE;IV (INFUSION)021227-002Jan 26, 2001RXYes6,136,783*PED<disabled>Y<disabled>
Merck
CANCIDAS
caspofungin acetate
INJECTABLE;IV (INFUSION)021227-001Jan 26, 2001RXYes5,952,300*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: CANCIDAS

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck
CANCIDAS
caspofungin acetate
INJECTABLE;IV (INFUSION)021227-001Jan 26, 20015,378,804*PED<disabled>
Merck
CANCIDAS
caspofungin acetate
INJECTABLE;IV (INFUSION)021227-001Jan 26, 20015,792,746*PED<disabled>
Merck
CANCIDAS
caspofungin acetate
INJECTABLE;IV (INFUSION)021227-002Jan 26, 20015,792,746*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: CANCIDAS

Drugname Dosage Strength RLD Submissiondate
caspofungin acetateFor Injection50 mg/vial and 70 mg/vialCancidas6/26/2009

Non-Orange Book Patents for Tradename: CANCIDAS

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,378,804 Aza cyclohexapeptide compounds<disabled in preview>
5,792,746 Aza cyclohexapeptide compounds<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: CANCIDAS

Country Document Number Estimated Expiration
Poland187294<disabled in preview>
Bulgaria64272<disabled in preview>
Spain2139043<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: CANCIDAS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0036France<disabled>PRODUCT NAME: THALIDOMIDE; REGISTRATION NO/DATE: EU/1/08/443/001 20080416
C0054France<disabled>PRODUCT NAME: CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001 20011024
00076Netherlands<disabled>PRODUCT NAME: CASPOFUNGINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT, IN HET BIJZONDER CASPOFUNGINE ACETAAT; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Connect with Social Media:

`abc